

## Title (en)

GENE SEQUENCE VARIATIONS WITH UTILITY IN DETERMINING THE TREATMENT OF DISEASE

## Title (de)

GENSEQUENZ-VARIATIONEN NÜTZLICH FÜR DIE BESTIMMUNG DER BEHANDLUNGSMETHODE BEI KRANKHEITEN

## Title (fr)

VARIATIONS DE SEQUENCES GENIQUES PRESENTANT UNE UTILITE POUR LA SELECTION DU TRAITEMENT D'UNE MALADIE

## Publication

**EP 1224322 A2 20020724 (EN)**

## Application

**EP 00919254 A 20000120**

## Priority

- US 0001392 W 20000120
- US 12104799 P 19990222
- US 13944099 P 19990615
- US 35774399 A 19990720

## Abstract (en)

[origin: WO0050639A2] The present disclosure describes the use of genetic variance information for genes involved in gene pathways in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

## IPC 1-7

**C12Q 1/68**

## IPC 8 full level

**C12N 15/09** (2006.01); **A61K 45/00** (2006.01); **A61P 1/00** (2006.01); **A61P 1/16** (2006.01); **A61P 3/04** (2006.01); **A61P 3/10** (2006.01); **A61P 5/00** (2006.01); **A61P 5/14** (2006.01); **A61P 5/18** (2006.01); **A61P 5/38** (2006.01); **A61P 7/00** (2006.01); **A61P 7/06** (2006.01); **A61P 9/00** (2006.01); **A61P 9/04** (2006.01); **A61P 9/06** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 11/00** (2006.01); **A61P 11/06** (2006.01); **A61P 13/02** (2006.01); **A61P 13/12** (2006.01); **A61P 15/00** (2006.01); **A61P 15/16** (2006.01); **A61P 15/18** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 17/10** (2006.01); **A61P 17/14** (2006.01); **A61P 19/00** (2006.01); **A61P 19/02** (2006.01); **A61P 19/10** (2006.01); **A61P 21/00** (2006.01); **A61P 25/00** (2006.01); **A61P 25/04** (2006.01); **A61P 25/06** (2006.01); **A61P 25/08** (2006.01); **A61P 25/14** (2006.01); **A61P 25/16** (2006.01); **A61P 25/18** (2006.01); **A61P 25/22** (2006.01); **A61P 25/24** (2006.01); **A61P 25/28** (2006.01); **A61P 29/00** (2006.01); **A61P 35/00** (2006.01); **A61P 37/02** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/68** (2006.01)

## CPC (source: EP)

**A61P 1/00** (2017.12); **A61P 1/16** (2017.12); **A61P 3/04** (2017.12); **A61P 3/10** (2017.12); **A61P 5/00** (2017.12); **A61P 5/14** (2017.12); **A61P 5/18** (2017.12); **A61P 5/38** (2017.12); **A61P 7/00** (2017.12); **A61P 7/06** (2017.12); **A61P 9/00** (2017.12); **A61P 9/04** (2017.12); **A61P 9/06** (2017.12); **A61P 9/08** (2017.12); **A61P 9/10** (2017.12); **A61P 9/12** (2017.12); **A61P 11/00** (2017.12); **A61P 11/06** (2017.12); **A61P 13/02** (2017.12); **A61P 13/12** (2017.12); **A61P 15/00** (2017.12); **A61P 15/16** (2017.12); **A61P 15/18** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 17/10** (2017.12); **A61P 17/14** (2017.12); **A61P 19/00** (2017.12); **A61P 19/02** (2017.12); **A61P 19/10** (2017.12); **A61P 21/00** (2017.12); **A61P 25/00** (2017.12); **A61P 25/04** (2017.12); **A61P 25/06** (2017.12); **A61P 25/08** (2017.12); **A61P 25/14** (2017.12); **A61P 25/16** (2017.12); **A61P 25/18** (2017.12); **A61P 25/22** (2017.12); **A61P 25/24** (2017.12); **A61P 25/28** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 37/02** (2017.12); **C12Q 1/6883** (2013.01); **C12Q 2600/106** (2013.01); **C12Q 2600/136** (2013.01); **C12Q 2600/142** (2013.01); **C12Q 2600/156** (2013.01); **C12Q 2600/158** (2013.01); **C12Q 2600/172** (2013.01); **Y02A 90/10** (2017.12)

## Citation (search report)

See references of WO 0050639A2

## Citation (examination)

- TONSTAD ET AL: "The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine", JOURNAL OF PEDIATRICS, vol. 132, no. 2, February 1998 (1998-02-01), MOSBY-YEAR BOOK, ST. LOUIS, MO, US, pages 365 - 368, XP005692954
- NELEN ET AL: "Methylenetetrahydrofolate reductase polymorphism affects the change in homocysteine and folate concentrations resulting from low dose folic acid supplementation in women with unexplained recurrent miscarriages", J OF NUTRITION, vol. 128, no. 8, August 1998 (1998-08-01), pages 1336 - 1341
- DELOUGHERRY ET AL: "Common mutation in methylenetetrahydrofolate reductase, Correlation with homocystein metabolism and late-onset vascular disease", CIRCULATION, vol. 94, 1996, pages 3074 - 3078
- HOL F.A. ET AL: "Molecular genetic analysis of the gene encoding the trifunctional enzyme MTHFD in patients with neural tube defects", CLINICAL GENETICS, vol. 53, no. 2, February 1998 (1998-02-01), COPENHAGEN, DK, pages 119 - 125, XP008059705
- ROY ET AL: "Different Antifolate-resistant L1210 Cell Variants with either increased or decreased folylpolyglutamate synthase gene expression at the level of mRNA transcription", JOURNAL BIOLOGICAL CHEMISTRY, vol. 270, no. 45, 10 November 1995 (1995-11-10), pages 26918 - 26922
- MORAN R.G.: "Roles of folylpoly-gamma-glutamate synthase in therapeutics with tetrahydrofolate antimetabolites: an overview", SEMINARS IN ONCOLOGY, vol. 26, no. 2, SUPPL. 6, April 1999 (1999-04-01), W.B. SAUNDERS, US, pages 24 - 32, XP000857939
- SANGHANI P.C.; SANGHANI S.P.; MORAN R.G.: "Localization of the active site of recombinant human folylpoly-gamma-glutamate synthetase using active site labeling and site directed mutagenesis", FASEB JOURNAL, vol. 11, no. 9, August 1997 (1997-08-01), BETHESDA, MD, US, pages A1139, XP008073804

## Cited by

CN112292730A

## Designated contracting state (EPC)

AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

## DOCDB simple family (publication)

**WO 0050639 A2 20000831**; **WO 0050639 A3 20020510**; AU 3997300 A 20000914; CA 2362533 A1 20000831; EP 1224322 A2 20020724; JP 2003516111 A 20030513

## DOCDB simple family (application)

**US 0001392 W 20000120;** AU 3997300 A 20000120; CA 2362533 A 20000120; EP 00919254 A 20000120; JP 2000601202 A 20000120